SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin developing new drugs to treat cancer, metabolic disorders

14 Jan 2019 Evaluate

Lupin is developing a pipeline of products under its new drug discovery programme to treat various diseases like cancer and metabolic disorders. The Novel Drug Discovery and Development (NDDD) is focused and committed on developing a pipeline of highly differentiated and innovative new chemical entities in various therapeutic areas like oncology, immunology and metabolic disorders.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2249.70 -128.20 (-5.39%)
11-May-2026 15:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1282.15
Cipla 1304.70
Zydus Lifesciences 960.00
Lupin 2249.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×